Contact Us
GLP-1 • GIP • Glucagon • Body composition

GLP-1 Peptides Compared: Fat Loss, Muscle Loss, Side Effects & Stacking Logic

Semaglutide, Tirzepatide, and Retatrutide are often grouped together, but they are not the same tool. They affect different gut-hormone pathways, which changes appetite, insulin response, liver glucose output, energy expenditure, fat loss, and side-effect patterns.

This guide explains what the pancreas does, what the liver does, why insulin sensitivity matters, why muscle loss happens during rapid weight loss, and why compounds like MOTS-c, AOD9604, 5-Amino-1MQ, and SLU-PP-332 are discussed as complementary research compounds.

Compare Results Stacking Guide

The simple version

GLP-1 mainly reduces appetite and improves glucose handling. GIP adds another incretin signal that may affect insulin response and nutrient partitioning. Glucagon can increase liver glucose release but also raises energy expenditure and fat oxidation.

Semaglutide: GLP-1 focused
Tirzepatide: GLP-1 + GIP dual agonist
Retatrutide: GLP-1 + GIP + glucagon triple agonist
Muscle loss is mostly from calorie deficit, rapid weight loss, lower protein, and less training
Complementary stacks should target different pathways, not duplicate the same receptor signal
Educational and research-use information only. This page is not medical advice, dosing guidance, treatment instruction, injection instruction, or a recommendation for human or animal use.
Receptors Study Results Pancreas & Liver Side Effects Muscle Loss Mitigation Complementary Compounds PepsVN Links
Receptor Targets

Semaglutide vs Tirzepatide vs Retatrutide

People often ask for exact percentages for GLP-1, GIP, and glucagon activity. That is not how these drugs should be compared. Receptor pharmacology depends on binding affinity, potency, tissue expression, dose, exposure time, and downstream signaling. So the chart below uses practical relative pathway emphasis, not exact biological percentages.

Compound Receptor profile Relative pathway emphasis What that means in plain English
Semaglutide GLP-1 receptor agonist
GLP-1
High
GIP
None
Glucagon
None
 Mostly appetite suppression, slower gastric emptying, increased glucose-dependent insulin secretion, and reduced inappropriate glucagon signaling.
Tirzepatide Dual GIP + GLP-1 receptor agonist
GLP-1
High
GIP
High
Glucagon
None
 Adds GIP signaling to GLP-1, which may support stronger glucose control, insulin response after meals, and improved body-composition outcomes.
Retatrutide Triple GIP + GLP-1 + glucagon receptor agonist
GLP-1
High
GIP
High
Glucagon
Added
 Combines appetite and glucose effects with a glucagon signal that is researched for increased energy expenditure, fat oxidation, and liver-metabolism effects.
Important: The bar chart is an educational pathway map, not a lab-measured percentage. Do not publish fake “33/33/33” style numbers. Retatrutide is not simply “one-third GLP-1, one-third GIP, one-third glucagon.”
Study Results

Weight loss, fat loss, lean mass loss, and tolerability

Trial results are not perfectly comparable because study length, population, dose escalation, adherence, and measurement methods differ. Still, they show the general pattern: more receptor pathways tend to produce more weight loss, but often with more gastrointestinal side-effect management needed.

Compound Major research signal Approx. weight-loss signal Fat vs lean mass Common side effects
Semaglutide GLP-1 focused appetite and glucose pathway Often discussed around ~15% average weight loss in obesity trials. Fat mass decreases substantially, but lean mass also falls. Some analyses estimate a relatively large lean-mass fraction of total weight lost. Nausea, constipation, diarrhea, reflux, reduced appetite, vomiting, fatigue, dehydration risk if intake drops too low.
Tirzepatide Dual incretin pathway: GLP-1 + GIP Often discussed around ~20%+ average weight loss in higher-dose obesity trials. Body-composition analyses suggest most loss is fat mass, with lean mass loss commonly around one-quarter of total weight lost. Similar GI pattern: nausea, diarrhea, constipation, vomiting, reflux, appetite suppression. Side effects often depend on dose escalation speed.
Retatrutide Triple agonist: GLP-1 + GIP + glucagon Phase 2 showed very large weight-loss signals; newer Phase 3 updates report even stronger average loss over longer study periods. Still being studied. Because total weight loss is larger, lean-mass preservation becomes especially important even if the percentage split is similar. GI effects remain central: nausea, vomiting, diarrhea, constipation, appetite suppression, and dose-related tolerability concerns.
Research takeaway: Semaglutide is mainly GLP-1. Tirzepatide adds GIP. Retatrutide adds glucagon signaling on top of GLP-1 and GIP. That extra glucagon pathway is one reason Retatrutide is so interesting for fat loss, energy expenditure, and liver-metabolism research.
Mechanism

What the pancreas and liver are doing

The most useful way to understand these compounds is to look at the organ-level signals: brain, stomach, pancreas, liver, muscle, and fat tissue.

Pancreas

Insulin release

GLP-1 and GIP both help the pancreas release insulin in a glucose-dependent way. That means the signal is stronger when glucose is elevated and less active when glucose is low.

This is why incretin compounds are researched for glucose control as well as weight management.

Pancreas

Glucagon control

GLP-1 tends to suppress inappropriate glucagon release from alpha cells. That matters because glucagon tells the liver to release glucose.

In type 2 diabetes research, reducing inappropriate liver glucose output is a big part of improving fasting glucose.

Liver

Glucose output

The liver stores glucose as glycogen and can release glucose when the body needs it. Glucagon increases that release.

Retatrutide is interesting because glucagon can increase energy expenditure while GLP-1 and GIP help balance glucose and appetite signals.

Muscle

Insulin sensitivity

Better insulin sensitivity means muscle and other tissues respond to insulin more effectively, so glucose can move out of the blood and into cells more efficiently.

Weight loss itself improves insulin sensitivity, but compounds like MOTS-c are researched specifically for muscle glucose uptake and AMPK signaling.

Fat tissue

Energy storage vs release

Fat tissue is not just passive storage. It responds to insulin, inflammation, calorie balance, and hormone signals.

Compounds like AOD9604 and 5-Amino-1MQ are discussed because they target fat metabolism from different angles than GLP-1 appetite suppression.

Brain / gut

Appetite and fullness

GLP-1 pathways reduce appetite, increase fullness, and slow gastric emptying. That is useful, but it can also reduce protein intake if researchers are not careful.

Less food is not automatically better if lean mass, hydration, minerals, or protein intake collapse.

Side Effects

Why GLP-1 side effects happen

Most common side effects are tied to the same mechanisms that make these compounds effective: slower gastric emptying, stronger fullness signals, lower food intake, and altered gut-brain signaling.

GI

Nausea and vomiting

Slower stomach emptying and stronger satiety signaling can make food sit longer and make meals feel heavier. Fast dose escalation often makes this worse.

GI

Constipation or diarrhea

Gut motility changes, lower food volume, lower fluid intake, and lower fiber intake can all shift bowel patterns.

Nutrition

Low intake problems

Appetite suppression can accidentally become protein suppression, hydration suppression, and micronutrient suppression. That is where fatigue and lean-mass loss become more likely.

Practical research concept: Side-effect mitigation is usually about reducing shock to the system: slower escalation, smaller meals, higher protein density, better hydration, electrolytes, fiber, and avoiding heavy high-fat meals when gastric emptying is slowed.
Body Composition

Why muscle loss happens during GLP-1 weight loss

GLP-1 compounds do not simply “burn muscle.” Lean mass loss usually happens because rapid weight loss changes the whole environment: less food, less protein, less training stimulus, less mechanical loading, and lower total energy availability.

Cause 1

Calorie deficit

When energy intake drops sharply, the body uses stored energy. Most comes from fat, but some can come from lean tissue, especially if protein and training are poor.

Cause 2

Low protein intake

Appetite suppression often makes people eat less of everything. If protein falls too low, muscle protein synthesis has fewer building blocks.

Cause 3

No resistance training

Muscle is expensive tissue. Without mechanical tension from lifting or resistance work, the body has less reason to keep it during a large deficit.

Mitigation

How researchers think about preserving lean mass

The goal is not just weight loss. Better research design looks at fat loss, lean mass, strength, glucose control, energy, adherence, and side-effect tolerance.

Strategy Mechanism Why it matters
Resistance training Mechanical tension activates muscle-retention signaling, including pathways related to muscle protein synthesis. Gives the body a reason to keep lean tissue while fat mass drops.
Higher protein density Supports amino acid availability and muscle protein synthesis during low appetite periods. Important because GLP-1 appetite suppression can make total protein intake accidentally too low.
Slower rate of loss Reduces the severity of the energy deficit and may improve training quality and nutrient intake. Very rapid loss can increase the chance that lean mass, performance, and recovery suffer.
Insulin sensitivity support Improved glucose uptake and nutrient partitioning may support training energy and metabolic flexibility. This is where MOTS-c, exercise, and mitochondrial research become interesting.
Hydration, fiber, electrolytes Supports GI function and reduces constipation, fatigue, and dehydration risk. Useful because appetite suppression often reduces fluid and food volume too.
Complementary Compounds

Compounds researched alongside GLP-1 pathways

The most logical complements do not simply add more GLP-1 activity. They target different mechanisms: mitochondrial function, insulin sensitivity, fat oxidation, lipolysis, energy expenditure, or lean-mass preservation.

MOTS-c

Researched for AMPK signaling, skeletal-muscle glucose uptake, mitochondrial function, and insulin sensitivity. Mechanistically, this complements GLP-1 drugs because it targets cellular energy and glucose handling rather than appetite alone.

AOD9604

Researched for fat-metabolism and lipolysis-related pathways. It is discussed as complementary because it does not primarily work through appetite suppression.

5-Amino-1MQ

Researched as an NNMT inhibitor. NNMT is involved in NAD and methylation-related metabolism, and inhibition is studied for fat-mass and metabolic-efficiency effects.

SLU-PP-332

Researched as an ERR agonist and “exercise-mimetic” style compound. Interest is around energy expenditure, oxidative metabolism, and endurance-like pathway activation.

Tesamorelin

Researched through the GHRH pathway and body-composition studies, especially visceral fat-related research. It targets a different endocrine axis than GLP-1.

GHK-Cu / KLOW

Not fat-loss compounds, but often discussed for skin, collagen, recovery, and tissue remodeling during body-composition change.

Need help comparing GLP-1 research compounds?

Message PepsVN for help understanding Retatrutide, Tirzepatide, MOTS-c, AOD9604, 5-Amino-1MQ, reconstitution math, and stacking logic.

Important Disclaimer:

This page is for educational and research-use information only. It is not medical advice, legal advice, dosing guidance, treatment guidance, injection instruction, or a recommendation for human or animal use. Retatrutide is investigational and not approved for public medical use. Peptides and related compounds may be regulated differently depending on jurisdiction. Readers are responsible for understanding and complying with applicable laws and regulations.